<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002721'>Immune deficiency</z:hpo>, especially to the Epstein-Barr virus, and increased susceptibility to <z:e sem="disease" ids="C1264624" disease_type="Disease or Syndrome" abbrv="">fatal infectious mononucleosis</z:e>, acquired agammoglobulinemia, and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are the cardinal features of the <z:hpo ids='HP_0001417'>X-linked</z:hpo> lymphoproliferative syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Since the establishment of the XLP Registry in September, 1978, 59 affected males in seven unrelated kindreds were comprehensively studied </plain></SENT>
<SENT sid="2" pm="."><plain>A spectrum of lymphoproliferative phenotypes was observed </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-four patients (57%) died from <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, eight (14%) had <z:e sem="disease" ids="C1264624" disease_type="Disease or Syndrome" abbrv="">fatal infectious mononucleosis</z:e> with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> <z:hpo ids='HP_0100242'>sarcoma</z:hpo>), nine (15%) had depressed immunity following <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e>, and eight (14%) developed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Several patients with XLP lacked EBV antibodies despite <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> by EBV </plain></SENT>
<SENT sid="5" pm="."><plain>The results of this study suggest that EBV can be an oncogenic agent in patients who are immune deficient with XLP </plain></SENT>
</text></document>